Articles From: UPDATE: Stock futures gain; Apple to steal the show to Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance


2013/10/28
By Sara Sjolin, MarketWatch LONDON (MarketWatch) -- U.S. stock futures pointed to a higher open on Wall Street on Monday, with results from Apple Inc. likely to dominate corporate news, and industrial-production figures the highlight on the data calendar.
Sign-up for UPDATE: Stock futures gain; Apple to steal the show investment picks
2013/10/28
http://media.marketwire.com/attachments/201212/109000_36797_HP_Blue_RGB_72_MD.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1062673&ProfileId=051205&sourceType=1 PALO ALTO, CA --
Sign-up for Nikon Leverages HP Software to Deliver Inspiration and Education to Photographers on the Web investment picks
2013/10/28
VILLA GUARDIA (COMO), Italy, Oct.
Sign-up for Gentium to Report Third Quarter 2013 Financial Results investment picks
2013/10/28
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject in its phase 2/3 childhood cerebral adrenoleukodystrophy (CCALD) study, Starbeam (ALD-102) has undergone infusion with bluebird bio’s Lenti-D drug product in an autologous hematopoietic stem cell transplantation.
Sign-up for bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD investment picks
2013/10/28
Freescale Semiconductor, Ltd.
Sign-up for Freescale Announces Senior Secured Notes Offering investment picks
Fifield Companies Selects Textura-CPM Enterprise™ Canada NewsWire Developer Improves Transparency and Reduces Risk with Construction Payment Management Solution CHICAGO , Oct.
Sign-up for Fifield Companies Selects Textura-CPM Enterprise™ investment picks
2013/10/28
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results of three long-term (52-week) phase III studies of apremilast, the Company’s first-in-class, oral, targeted inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego.
Sign-up for Oral Apremilast Demonstrated Long-Term Clinical Benefits for Patients with Psoriatic Arthritis investment picks
IMAX Partners With Content Distributor PRIMA Cinema To Provide Current Theatrical Releases In The Home Canada NewsWire Agreement with PRIMA Cinema Enables Customers to Experience Day-and-Date Movies Enhanced with IMAX Proprietary Technology LOS ANGELES , Oct.
Sign-up for IMAX Partners With Content Distributor PRIMA Cinema To Provide Current Theatrical Releases In The Home investment picks
2013/10/28
Agreement with PRIMA Cinema Enables Customers to Experience Day-and-Date Movies Enhanced with IMAX Proprietary Technology LOS ANGELES , Oct.
Sign-up for IMAX Partners With Content Distributor PRIMA Cinema To Provide Current Theatrical Releases In The Home investment picks
2013/10/28
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced the presentation of efficacy and safety data from a Phase IIb dose-ranging study of subcutaneous (SC) clazakizumab in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine rather than its receptor.
Sign-up for Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology investment picks
2013/10/28
Avidus Completes Private Placement Canada NewsWire VANCOUVER, BC and MESA, AZ , Oct.
Sign-up for Avidus Completes Private Placement investment picks
VANCOUVER, BC and MESA, AZ , Oct.
Sign-up for Avidus Completes Private Placement investment picks
RTI International Metals, Inc., (NYSE: RTI), will host a live conference call Thursday, November 7, 2013, at 10:00 a.m. Eastern Time to discuss the Company’s third quarter 2013 results, which will be released before the market opens that morning.
Sign-up for RTI International Metals Announces 2013 Third Quarter Results Conference Call Schedule investment picks
2013/10/28
AltraHD Maximizes Performance while Minimizing the Storage footprint of Hadoop Clusters FREMONT, Calif.
Sign-up for Exar Delivers Industry-First Hardware-Accelerated Compression Solution for Apache Hadoop investment picks
Tenneco Inc. (NYSE:TEN) reported third quarter net income of $12 million, or 19-cents per diluted share, which includes $59 million in restructuring expense.
Sign-up for Tenneco Reports Third Quarter Results investment picks
2013/10/28
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced research findings on apremilast, the Company’s first-in-class, oral, targeted inhibitor of phosphodiesterase 4 (PDE4), based on pooled data analyses from three randomized, controlled, phase III trials in psoriatic arthritis—PALACE 1, 2 and 3—at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego.
Sign-up for Oral Apremilast Demonstrated Clinically Meaningful and Statistically Significant Improvements in Enthesitis and Dactylitis investment picks
2013/10/28
PENNSAUKEN, N.J., Oct.
Sign-up for RCM Technologies Announces New $5 Million Stock Repurchase Program investment picks
2013/10/28
AUSTIN, Texas, Oct.
Sign-up for Founders Appointed as Co-Chairmen of the Board of Directors of Chuy's Holdings, Inc. investment picks
2013/10/28
UrtheCast Cameras Complete Testing, Ship To Baikonur Cosmodrome Canada NewsWire SOURCE UrtheCast Corp.
Sign-up for UrtheCast Cameras Complete Testing, Ship To Baikonur Cosmodrome investment picks
Developer Improves Transparency and Reduces Risk with Construction Payment Management Solution CHICAGO , Oct.
Sign-up for Fifield Companies Selects Textura-CPM Enterprise™ investment picks
2013/10/28
ZHUHAI, China , Oct.
Sign-up for Actions Semiconductor to Report Third Quarter 2013 Financial Results on November 6, 2013 investment picks
2013/10/28
By Tess Stynes Merck & Co.'s (MRK) third-quarter earnings fell 35% as the loss of exclusivity for asthma and allergy drug Singulair contributed to weaker sales.
Sign-up for Merck 3rd-Quarter Profit Down 35% on Sales Drop, Restructuring Expenses investment picks
2013/10/28
Romarco Receives Three Key State Permits for Haile Canada NewsWire TRADING SYMBOL: TSX: R TORONTO , Oct.
Sign-up for Romarco Receives Three Key State Permits for Haile investment picks
2013/10/28
TRADING SYMBOL: TSX: R TORONTO , Oct.
Sign-up for Romarco Receives Three Key State Permits for Haile investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1062800&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Small Cap Specialists Issues Research on Public Companies That Have Expansion Plans on the Horizon investment picks
NEW YORK (MarketWatch) -- Merck & Co.
Sign-up for Merck third-quarter profit, revenue fall investment picks
2013/10/28
Biogen Idec Inc. (NASDAQ:BIIB) today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012.
Sign-up for Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: UPDATE: Stock futures gain; Apple to steal the show to Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity